Point72 Asia (Singapore)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Point72 Asia (Singapore)’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$1.27M	Buy	+4,527	New	+$1.23M	0.2%	92
2025 Q1	–	Sell	-1,909	Closed	-$627K	–	887
2024 Q4	$627K	Buy	1,909 +478	+33%	+$162K	0.17%	117
2024 Q3	$479K	Buy	+1,431	New	+$454K	0.09%	181
2024 Q2	–	Sell	-2	Closed	-$537	–	1072
2024 Q1	$537	Buy	+2	New	+$658	﹤0.01%	1028

Other funds holding BIO

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Point72 Asia (Singapore)'s BIO Position: Q3 2025 in Review

Point72 Asia (Singapore) opened a new position in Bio-Rad Laboratories Class A (BIO) in Q3 2025: 4,527 shares worth $1.27M. The stake represents 0.2% of the portfolio and ranks #92 among its holdings. This is a return to the name: Point72 Asia (Singapore) previously reported a position in BIO as recently as Q4 2024.

Point72 Asia (Singapore) first reported a position in BIO in Q1 2024 and has held it in 4 quarters since. 396 funds tracked by Wall St. Rank hold BIO as of Q3 2025.

Point72 Asia (Singapore) held 4,527 shares of Bio-Rad Laboratories Class A worth $1.27M as of Q3 2025.
Bio-Rad Laboratories Class A was a new Point72 Asia (Singapore) position in Q3 2025.
Bio-Rad Laboratories Class A made up 0.2% of Point72 Asia (Singapore)'s portfolio in Q3 2025, its #92 holding.
Point72 Asia (Singapore) first reported a position in Bio-Rad Laboratories Class A in Q1 2024 and has held it in 4 quarters since.
396 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.